VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:VX1 • US92532F1003

399.85 EUR
+4.15 (+1.05%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to VX1. VX1 was compared to 85 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 is growing strongly while it is still valued neutral. This is a good combination! These ratings could make VX1 a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • VX1 had positive earnings in the past year.
  • In the past year VX1 had a positive cash flow from operations.
  • Of the past 5 years VX1 4 years were profitable.
  • Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • With an excellent Return On Assets value of 14.78%, VX1 belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
  • With an excellent Return On Equity value of 21.22%, VX1 belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
  • VX1 has a Return On Invested Capital of 15.66%. This is amongst the best in the industry. VX1 outperforms 94.05% of its industry peers.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 17.53%. This is significantly above the industry average of 11.98%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • With an excellent Profit Margin value of 31.35%, VX1 belongs to the best of the industry, outperforming 88.10% of the companies in the same industry.
  • VX1's Operating Margin of 38.70% is amongst the best of the industry. VX1 outperforms 94.05% of its industry peers.
  • VX1's Operating Margin has improved in the last couple of years.
  • VX1 has a better Gross Margin (86.28%) than 82.14% of its industry peers.
  • VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, VX1 has less shares outstanding
  • VX1 has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for VX1 has been reduced compared to a year ago.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.77
WACC8.86%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.36 indicates that VX1 has no problem at all paying its short term obligations.
  • VX1's Current ratio of 2.36 is in line compared to the rest of the industry. VX1 outperforms 51.19% of its industry peers.
  • A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 2.00, VX1 perfoms like the industry average, outperforming 48.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3303.92%, which is quite impressive.
  • Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
  • VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.33%.
  • VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%

3.2 Future

  • VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 150.51% yearly.
  • The Revenue is expected to grow by 9.75% on average over the next years. This is quite good.
EPS Next Y6350.49%
EPS Next 2Y738.46%
EPS Next 3Y328.92%
EPS Next 5Y150.51%
Revenue Next Year10.11%
Revenue Next 2Y9.4%
Revenue Next 3Y9.51%
Revenue Next 5Y9.75%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 27.16, the valuation of VX1 can be described as expensive.
  • VX1's Price/Earnings ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 79.76% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (27.92), we can say VX1 is valued inline with the index average.
  • With a Price/Forward Earnings ratio of 23.13, VX1 is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, VX1 is valued a bit cheaper than the industry average as 79.76% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (27.78), we can say VX1 is valued inline with the index average.
Industry RankSector Rank
PE 27.16
Fwd PE 23.13
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than the industry average as 76.19% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 80.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 35.85
EV/EBITDA 23.93
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of VX1 may justify a higher PE ratio.
  • A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.92% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y738.46%
EPS Next 3Y328.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

FRA:VX1 (2/6/2026, 7:00:00 PM)

399.85

+4.15 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-12
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap101.45B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.92
Price Target449.01 (12.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)5.57%
PT rev (3m)7.33%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)0.75%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 27.16
Fwd PE 23.13
P/S 10.21
P/FCF 35.85
P/OCF 32.18
P/B 6.91
P/tB 7.57
EV/EBITDA 23.93
EPS(TTM)14.72
EY3.68%
EPS(NY)17.29
Fwd EY4.32%
FCF(TTM)11.15
FCFY2.79%
OCF(TTM)12.42
OCFY3.11%
SpS39.18
BVpS57.88
TBVpS52.8
PEG (NY)0
PEG (5Y)N/A
Graham Number138.45
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC8.86%
ROIC/WACC1.77
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6350.49%
EPS Next 2Y738.46%
EPS Next 3Y328.92%
EPS Next 5Y150.51%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.11%
Revenue Next 2Y9.4%
Revenue Next 3Y9.51%
Revenue Next 5Y9.75%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 8 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 6350.49% in the next year.